Teva Pharma (TEVA) Reports In-Line Q2 EPS; Lowers Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Reports Second Quarter 2021 Financial Results
July 28, 2021 7:00 AM EDTRevenues of $3.9 billion GAAP diluted EPS of $0.19 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $218 million Free cash flow of $625 million 2021 revenue outlook revised lower to reflect ongoing impact of COVID-19; all other key components reaffirmed: Net revenues of $16.0 - $16.4 billion vs. previous range of $16.4 - $16.8 billion Adjusted EBITDA of $4.8 - $5.1 billion EPS of $2.50 - $2.70 Free cash flow of $2.0 - $2.3 billion
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:... More
